News

BioNTech SE (BNTX) Q2 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships ...

BioNTech SE (BNTX) reports significant revenue growth and strategic advancements despite ongoing challenges in the COVID-19 ...

BioNTech's Q2 revenues double on higher COVID vaccine sales

German biotech firm BioNTech on Monday said that second-quarter revenues more than doubled to 261 million euros ($302 million ...

BioNTech posts Q2 beat as revenue more than doubles

BioNTech (BNTX) stock gains as the company surpasses Q2 2025 forecasts with 103% YoY revenue growth, thanks mainly to Pfizer ...
InvestorsHub on MSN5d

BioNTech shares climb over 2% as Q2 revenue doubles, Bristol Myers partnership boosts outlook

BioNTech SE (NASDAQ:BNTX) saw its shares rise 2.45% in pre-market trading Monday following a strong second-quarter report ...

These Analysts Revise Their Forecasts On BioNTech After Q2 Results

BioNTech reaffirmed its fiscal year 2025 guidance of 1.7 billion-2.2 billion euros compared to the consensus of 2.05 billion ...

BioNTech Narrows Losses, Q2 Revenue Doubles As Vaccine Collaboration Drives Growth

“In the second quarter, we took significant steps to advance BioNTech into a multiproduct biotechnology company by ...
Stocktwits on MSN4d

BioNTech Gets Price Target Bumps From BofA, Clear Street After Strong Q2, Oncology Pipeline Push

BioNTech is back in Wall Street’s spotlight after posting better-than-expected second-quarter results and doubling down on ...

BioNTech price target raised to $185 from $181 at Clear Street

Clear Street raised the firm’s price target on BioNTech (BNTX) to $185 from $181 and keeps a Buy rating on the shares after updating the firm’s model to a year-end 2026 valuation following the company ...